Dr. Nandkishore Vijay Ranadive, MD

Dr. Ranadive practices at Orlando Heart Specialists, P.A. in Apopka, Florida.

Dr. Ranadive's NPI, 1235150103, was assigned on July 23, 2006. Dr. Ranadive graduated from Baroda Medical College in 1984. Dr. Ranadive holds Florida license ME62024.

Dr. Ranadive's primary practice is Orlando Heart Specialists, P.A., at 33 S Washington Ave, Apopka, FL 32703 in Orange County. The practice phone is (407) 767-8554.

Dr. Ranadive's primary practice is Orlando Heart Specialists, P.A. in Apopka, Florida. Dr. Ranadive is also affiliated with AdventHealth Orlando. The medical group on file is Orlando Heart & Vascular Institute. Dmand AI also links Dr. Ranadive to 1 more hospital, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ranadive practices, 5 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Ranadive's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Ranadive is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Ranadive's licenses on file in 3 states: Florida, New Jersey and New York.

Dmand AI lists angioplasty, cardiac catheterization, leg revascularization, pacemaker or defibrillator implantation, pacemaker replacement and varicose vein treatment among the conditions Dr. Ranadive treats.

CMS data shows 8,349 Medicare services from Dr. Ranadive across 43 procedure codes in 2024, for 1,440 Medicare patients. Medicare paid $769,712 for them.

CMS counts 1,440 Medicare patients who saw Dr. Ranadive in 2024. The largest group is 75 to 84, with 604 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ranadive's median patient age at 75, with 52% women.

In 2024, Dr. Ranadive wrote 10,903 Medicare Part D claims for 1,548 patients. 82% of them were for generic drugs. CMS names the drug for 10,275 of them, across 101 drugs with 11 or more claims each, at $2,555,148 in total drug cost. In 2023, CMS named 10,470 claims across 103 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ranadive for performance year 2024, reported as part of a group. Dr. Ranadive accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 46 procedures of varicose vein removal by Dr. Ranadive, more than 73% of the clinicians it reports for that procedure.

Coronary angioplasty and stenting: 1 to 10 procedures (CMS shows small counts as a range)

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Ranadive to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic and Ventricular Dysfunction, Left. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Ranadive that name 2 trials.

CMS Open Payments shows 756 general payments to Dr. Ranadive from 60 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Pfizer Inc. paid the most, $19,937. It also lists 5 research payments totaling $26,898 from 2020 to 2023, naming 2 clinical trials.

Dmand AI lists 2 awards for Dr. Ranadive, most recently CMS Stage 1 EHR in 2013.

Dr. Ranadive graduated from Baroda Medical College in 1984. Dr. Ranadive is a member of ACC.

Dr. Ranadive is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.